NCT04251364

Treatment of Chronic Mountain Sickness

Acetazolamide and Statins for the Treatment of Chronic Mountain Sickness in Highlanders: A Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Centre d'Expertise sur l'Altitude EXALT · Academic / Other
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the effect of two drugs for the treatment of chronic mountain sickness in highlanders.

Detailed description

About 100 million individuals reside at high altitude (\>2500m) worldwide, with the largest populations of highlanders being found in South America (Andean), central Asia (Tibetan and Sherpa) and East Africa (Ethiopian). Despite unique adaptations to hypoxia in these populations, chronic mountain sickness (CMS) is a clinical syndrome which is observed in 5-33% of individuals residing permanently at high altitude.Several pharmacological approaches have been proposed in the treatment of EE and CMS. However, few studies show sufficient clinical evidence for safety and efficacy in CMS treatment and most highlanders with CMS remain untreated. The present project aims to better characterize chronic hypoxic responses in highlanders and to evaluate the interest of acetazolamide and statins as potential treatments for chronic mountain sickness.

Conditions

• Hypoxia, Altitude

Interventions

Type	Name	Description
DRUG	Acetazolamide	Daily acetazolamide pill intake
DRUG	Atorvastatin	Daily atorvastatin pill intake
DRUG	Placebo oral tablet	Daily placebo pill intake

Timeline

• Start date: 2020-02-15
• Primary completion: 2021-10-30
• Completion: 2021-12-30
• First posted: 2020-01-31
• Last updated: 2025-07-31

Locations

1 site across 1 country: France